Tri-Modality Therapy with I-125 brachytherapy, external beam radiation therapy, and short- or long-term hormone therapy for high-risk localized prostate cancer (TRIP): study protocol for a phase III, multicenter, randomized, controlled trial

BMC Cancer, 04/03/2012

The present randomized controlled trial (RCT) is expected to provide additional insight regarding the potency and limitations of the addition of 2 years of adjuvant hormonal therapy (HT) to this trimodality approach, and to establish an appropriate treatment strategy for high–risk PCa.

Print Article Summary Cat 2 CME Report